Top

Journal of Gastrointestinal Surgery

Published in:

01-02-2010 | DeMeester Festschrift

Proton Pump Inhibitors in the Management of GERD

Authors: Philip O. Katz, Stacey Zavala

Published in: Journal of Gastrointestinal Surgery | Special Issue 1/2010

Abstract

Introduction

Management of gastroesophageal reflux disease (GERD) is based on the concept that gastric contents, principally acid and pepsin, are responsible for symptoms of reflux and esophageal injury. Pharmacologic treatment is based on the principle that controlling intragastric pH will affect esophageal healing and subsequently symptom relief.

Results and Discussion

Control of pH can be accomplished with antisecretory agents, principally proton pump inhibitors (PPIs). The majority of patients respond to a single daily dose of a PPI; however, some will require higher doses, and a small percentage are “refractory” to twice daily dosing of these drugs. The success of these agents, and in fact the reasons for “failure,” is elucidated by understanding the mechanism of action of PPIs and the effect of dose timing and meals on their efficacy.

Conclusion

Awareness of new concerns regarding potential side effects of PPIs when used long-term require careful thought as GERD is a chronic disease with most needing some form of medical treatment over time. This article reviews the pharmacologic properties of PPIs and the impact on the treatment of GERD.

Locke GR, Talley NJ, Fett SL et al. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmstead county, Minnesota. Gastroenterology 1997;112:1448.CrossRefPubMed

Stanghellini V. Relationship between upper gastrointestinal symptoms and lifestyle, psychosocial factors and comorbidity in general population; results from the Domestic/International Gastroenterology Surveillance Study (DIGEST). Scand J Gastroenterol Suppl 1999;231:29–37.PubMed

Fennerty MB. Extraesophageal gastroesophageal reflux disease. Presentations and approach to treatment. Gastroenterol Clin North Am 1999;28:861–873.CrossRefPubMed

Robinson M. Review article: Current perspectives on hypergastrinaemia and enterochromaffin-like-cell hyperdysplasia. Aliment Pharmacol Ther 1999;13(suppl 5):5–10.CrossRefPubMed

Massoomi F, Savage J, Destache CJ. Omeprazole: a comprehensive review. Pharmacotherapy 1993;13(1):46–59.PubMed

Maton PN. Omeprazole N. Engl J Med 1991;324(14):965–975.

Bell NJV, Burget D, Howden CW et al. Appropriate acid suppression for the management of gastro-oesophageal reflux disease. Digestion 1992;51(suppl 1):59–67.CrossRefPubMed

Lew EA. Review article: Pharmacokinetic concerns in the selection of anti-ulcer therapy. Aliment Pharmacol Ther 1999;13(suppl 5):11–16.CrossRefPubMed

Bensancon M, Simon A, Sachs G et al. Sites of action of the gastric H, K-ATPase with extracytoplasmic thiol reagents. J Biol Chem 1997;272:22438–22446.CrossRef

10.

Klinkenberg-Knol EC, Festen HPM, Meuwissen SGM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995;49:695–710.CrossRefPubMed

11.

Hatlebakk JG, Katz PO, Castell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. APT 2000;14(10):1267–1272.

12.

Katsube T, Adachi K, Kawamura A et al. Helicobacter pylori infection influences nocturnal gastric acid breakthrough. Aliment Pharmacol Ther 2000;14(8):1049–1056.CrossRefPubMed

13.

Castell D, Bagin R, Goldlust B, Major J, Hepburn B. Comparison of the effects of immediate-release omeprazole powder for oral suspension and pantoprazole delayed-release tablets on nocturnal acid breakthrough in patients with symptomatic gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2005;21(12):1467–1474.CrossRefPubMed

14.

Katz PO, Koch FK, Ballard ED, Bagin RG, Gautille TC, Checani GC, Hogan DL, Pratha VSV. Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms. Aliment Pharmacol Ther 2007;25:197–205.PubMed

15.

Physicans’ Desk Reference. Product information for all proton pump inhibitors, 60th edn. Thomson PDR: Montvale, NJ, 2006

16.

Hatlebakk JG, Katz PO, Kuo B et al. Nocturnal gastric acidity and acid breakthrough on different regimens of omeprazole 40 mg daily. Aliment Pharmacol Ther 1998;12:1235–1240.CrossRefPubMed

17.

Howden CW. Vitamin B12 levels during prolonged treatment with proton pump inhibitors. J Clin Gastroenterol 2000;30(1):29–33.CrossRefPubMed

18.

Laheij RJF, Sturkenboom MCHM, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004;292(16):1955–1960.CrossRefPubMed

19.

Dial S, Alrasadi K, Manoukian C et al. Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case-control studies. CMAJ: Can Med Assoc J 2004;171(1):33–38.CrossRef

20.

Dial S, Delaney JAC, Barkun AN, Suissa S. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile- associated disease. JAMA 2005;294(23):2989–2995.CrossRefPubMed

21.

Williams C, McColl KEL. Review article: Proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006;23(1):3–10.CrossRefPubMed

22.

Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ 2008;179(4):319–326.PubMed

23.

Yang Y-X, Lewis JD, Epstein S, Metz DC. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006;296(24):2947–2953.CrossRefPubMed

24.

Klinkenberg-Knol E, Nelis F, Dent J et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease. Gastroenterology 2000;118:661–669.CrossRefPubMed

25.

Tutuian R, Katz PO, Castell DO. A PPI is a PPI is a PPI: Lessons from prolonged intragastric pH monitoring. Gastroenterol 2000;118:A17.CrossRef

26.

Katz PO, Ginsberg GG, Hoyle PE, Sostek MB, Monyak JT, Silberg DG. Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis. Aliment Pharmacol Ther 2007;25(5):5617–5628.

27.

Richter JE, Kahrilas PJ, Johanson J et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001;96:656–665.CrossRefPubMed

28.

Castell DO, Kahrilas PJ, Richter JE et al. Esomeprazole (40 gm) compared with lansoprazole (30 mg0 in the treatment of erosive esophagitis. Am J Gastroenterol 2002;97(3):575–583.CrossRefPubMed

29.

Labenz J, Armstrong D, Lauritsen K et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther 2005;21(6):739–746.CrossRefPubMed

Title: Proton Pump Inhibitors in the Management of GERD
Authors: Philip O. Katz
Stacey Zavala
Publication date: 01-02-2010
Publisher: Springer-Verlag
Published in: Journal of Gastrointestinal Surgery / Issue Special Issue 1/2010
Print ISSN: 1091-255X
Electronic ISSN: 1873-4626
DOI: https://doi.org/10.1007/s11605-009-1015-3

At a glance: The STEP trials

Springer Medicine

Proton Pump Inhibitors in the Management of GERD

Abstract

Introduction

Results and Discussion

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Results and Discussion

Conclusion

Please log in to get access to this content

Other articles of this Special Issue 1/2010

Evaluation and Treatment of Superficial Esophageal Cancer

Future Applications of Flexible Endoscopy in Esophageal Surgery

Esophagectomy Without Mortality: What Can Surgeons Do?

Achalasia—If Surgical Treatment Fails: Analysis of Remedial Surgery

Emerging Concepts of Bile Reflux in the Constellation of Gastroesophageal Reflux Disease

High-resolution Esophageal Manometry: Using Technical Advances for Clinical Advantages